Canbridge Pharmaceuticals (HKSE:01228) Beta : N/A (As of Jun. 04, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Canbridge Pharmaceuticals Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-06-04), Canbridge Pharmaceuticals's Beta is Not available.

Canbridge Pharmaceuticals Beta Historical Data

The historical data trend for Canbridge Pharmaceuticals's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Canbridge Pharmaceuticals Beta Chart

Canbridge Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Beta

Canbridge Pharmaceuticals Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Beta	Get a 7-Day Free Trial				-	-	-	-	-

Competitive Comparison of Canbridge Pharmaceuticals's Beta

For the Biotechnology subindustry, Canbridge Pharmaceuticals's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Canbridge Pharmaceuticals's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Canbridge Pharmaceuticals's Beta distribution charts can be found below:

* The bar in red indicates where Canbridge Pharmaceuticals's Beta falls into.

Canbridge Pharmaceuticals Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Canbridge Pharmaceuticals (HKSE:01228) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Canbridge Pharmaceuticals Beta Related Terms

Thank you for viewing the detailed overview of Canbridge Pharmaceuticals's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.

Canbridge Pharmaceuticals (HKSE:01228) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Canbridge Pharmaceuticals Inc (HKSE:01228) » Definitions » Beta

Comparable Companies

Traded in Other Exchanges

MF1:Germany

Address

Building 21, No. 388 Xinping Street, Unit 18, 6th Floor, Suzhou Industrial Park,, Suzhou, CHN

Website

https://www.canbridgepharma.com

Canbridge Pharmaceuticals Inc is a global biopharmaceutical company. It is committed to the research, development, and commercialization of biotech therapies targeting rare diseases and rare oncology. The company's core product in the rare oncology area CAN008, is a glycosylated CD95-Fc fusion protein being developed for the treatment of glioblastoma multiforme (GBM). In the rare disease area, the company have seven biologics and small molecules products and product candidates for the treatment of Hunter Syndrome (MPS II) and other lysosomal storage disorders (LSDs), complement mediated disorders, hemophilia A, metabolic disorders, and rare cholestatic liver diseases including ALGS, PFIC and BA. Its pipeline consists of biologics, small molecules, and gene therapy solutions and 13 drugs.

Executives

Xue James Qun	2101 Beneficial owner
Athos Capital Limited	2102 Investment manager
Moskey Matthew Love	2201 Interest of corporation controlled by you
Schulte-hillen Friedrich Bela	2201 Interest of corporation controlled by you
Athos Asia Event Driven Master Fund	2101 Beneficial owner
Ctx Pharma Holdings Limited	2101 Beneficial owner
Kolchinsky Anna Inge Leonore Haas	2202 Interest of your spouse
Kolchinsky Peter	2305 Beneficiary of a trust
Ra Capital Management, L.p.	2102 Investment manager
Ra Capital Healthcare Fund Gp, Llc	2201 Interest of corporation controlled by you
Ra Capital Healthcare Fund, L.p.	2101 Beneficial owner
Wuxi Apptec Co., Ltd.
Qiming Corporate Gp Iv, Ltd.	2201 Interest of corporation controlled by you
Qiming Gp Iv, L.p.	2201 Interest of corporation controlled by you
Qiming Venture Partners Iv, L.p.	2101 Beneficial owner

Canbridge Pharmaceuticals (HKSE:01228) Headlines

No Headlines